Search

The ‘i4MDS’ consortium looks to the future at its second general meeting

Feb 29 2024 Posted in Meeting reports Tagged i4MDS

The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.

Read more

Mesenchymal Stromal Cells (MSC)

The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…

Read more

EHA2024 Scientific Congress Report

The European Hematology Association (EHA) is delighted to present the EHA2024 Scientific Congress Report titled “EHA Perspectives on Emerging Technologies in Hematology.

Read more

Publications

Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities

Lubbers, Bart R. ; Dombrink, Isabel; Kalina, Tomas; Hofmans, Mattias; Bruun, Morten S. ; Stanworth, Simon J. ; Béné, Marie C.

Read more

‘i4MDS’ consortium wins prestigious EHA Innovation Grant

In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.

Read more

Highlights from the SWG

On November 24, 2022, the SWG on Red Cells and Iron held its annual Business meeting virtually which was chaired by Prof. Ali Taher and Prof. Achille Iolascon.

Read more

Precision Hematology

The Precision Hematology Topics-in-Focus program will promote innovative concepts for diagnostics and innovative clinical trial designs, which should translate into the clinical application of precision hematology.

Read more

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Read more